Sanofi (SNY)
48.49
0.00 (0.00%)
Upcoming Events
Latest Headlines
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
January 30, 2023 1:00 AM - Globe NewsWire
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
January 30, 2023 1:00 AM - Globe NewsWire
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
January 27, 2023 1:00 AM - Globe NewsWire
Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
January 25, 2023 5:30 PM - Globe NewsWire
Denali Therapeutics (DNLI) Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
January 25, 2023 8:03 AM - StreetInsider
Sanofi (SAN:FP) (SNY) PT Raised to EUR90 at Barclays
January 25, 2023 4:14 AM - StreetInsider
Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference
January 24, 2023 6:01 AM - StreetInsider
Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare
January 18, 2023 7:00 AM - PR NewsWire
Form 6-K Sanofi For: Jan 17
January 17, 2023 2:08 PM - SEC Filing
Johnson & Johnson (JNJ) Cuts Production of Covid-19 Shot -- WSJ
January 13, 2023 10:48 AM - StreetInsider
Eli Lilly & Co. (LLY), Sanofi (SNY), Novo Nordisk (NVO) sued by California over insulin - Bloomberg
January 12, 2023 1:51 PM - StreetInsider
Citi Resumes Sanofi (SAN:FP) (SNY) at Buy
January 12, 2023 4:42 AM - StreetInsider
Citi Resumes Sanofi-Aventis (SNY) at Buy
January 12, 2023 3:37 AM - StreetInsider
Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M
January 11, 2023 11:30 AM - Globe NewsWire
Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants
January 5, 2023 2:00 AM - Globe NewsWire
Sanofi (SAN:FP) (SNY) PT Raised to EUR110 at Stifel
January 4, 2023 3:18 AM - StreetInsider
Press Release: Availability of the Q4 2022 Memorandum for modelling purposes
January 4, 2023 1:30 AM - Globe NewsWire
JPMorgan Reinstates Sanofi (SAN:FP) (SNY) at Overweight
January 3, 2023 1:28 AM - StreetInsider
Sanofi (SAN:FP) (SNY) PT Raised to EUR113 at Baader Helvea
December 29, 2022 3:45 AM - StreetInsider
Press Release: Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine
December 21, 2022 5:30 PM - Globe NewsWire
Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
December 21, 2022 5:29 PM - PR NewsWire
Sanofi (SNY) settles California Zantac case
December 21, 2022 12:09 PM - StreetInsider
Form 6-K Sanofi For: Dec 20
December 20, 2022 6:15 AM - SEC Filing
Goldman Sachs Reinstates Sanofi (SAN:FP) (SNY) at Buy
December 19, 2022 4:09 AM - StreetInsider
Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
December 19, 2022 1:00 AM - StreetInsider
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
December 19, 2022 1:00 AM - BizWire
Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
December 19, 2022 1:00 AM - Globe NewsWire
Regeneron (REGN), Sanofi (SNY) Announces Dupixent Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
December 16, 2022 7:30 AM - StreetInsider
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic esophagitis
December 16, 2022 7:30 AM - Globe NewsWire
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
December 16, 2022 7:29 AM - PR NewsWire
Regeneron (REGN) and Sanofi (SNY) Announce EU Approval of Dupixent for Prurigo Nodularis
December 15, 2022 5:47 AM - StreetInsider
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
December 15, 2022 1:00 AM - Globe NewsWire
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
December 15, 2022 12:59 AM - PR NewsWire
Sanofi (SAN:FP) (SNY) PT Raised to EUR97 at UBS
December 14, 2022 5:22 AM - StreetInsider
Morgan Stanley Resumes Sanofi (SAN:FP) (SNY) at Overweight
December 13, 2022 2:15 AM - StreetInsider
Sanofi shares rise after French drugmaker ditches Horizon deal talks
December 12, 2022 5:19 AM - StreetInsider
Amgen (AMGN) acquires Horizon (HZNP) for $26 billion as Sanofi (SNY) drops bid
December 12, 2022 5:17 AM - StreetInsider
European stocks weaken; caution ahead of central bank meetings
December 12, 2022 4:36 AM - StreetInsider
Amgen (AMGN) in advanced talks to acquire Horizon Therapeutics (HZNP) - WSJ
December 11, 2022 9:07 PM - StreetInsider
Press Release: Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”)
December 11, 2022 1:21 PM - Globe NewsWire
Sanofi (SNY) 30-day option implied volatility at 30
December 9, 2022 4:53 AM - StreetInsider
European stocks mixed; recession concerns clash with China reopening
December 7, 2022 4:12 AM - StreetInsider
Stifel Reiterates Buy Rating on Sanofi (SAN:FP) (SNY)
December 7, 2022 3:24 AM - StreetInsider
GSK, Pfizer, Sanofi fend off thousands of U.S. lawsuits over alleged Zantac cancer link
December 6, 2022 2:59 PM - StreetInsider
GSK (GSK), Sanofi (SNY) Jump After US Court Win In Zantac Litigation - Bloomberg
December 6, 2022 2:24 PM - StreetInsider
Sanofi (SNY) gaining with GSK, up 3.4%
December 6, 2022 2:05 PM - StreetInsider
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
December 6, 2022 1:26 AM - StreetInsider
Rumors Buzzing Around Wall Street Today
December 5, 2022 5:22 PM - StreetInsider
Horizon Therapeutics (HZNP) downticks as one of three bidders drops out
December 5, 2022 9:38 AM - StreetInsider
Form 6-K Sanofi For: Dec 02
December 2, 2022 10:41 AM - SEC Filing
Horizon Therapeutics (HZNP) Adds to Gains as Two Potential Bidders Disclose All-Cash Deal
December 2, 2022 10:07 AM - StreetInsider
Sanofi (SNY) Said Any Offer for Horizon Therapeutics plc (HZNP) Would Be All Cash
December 2, 2022 6:28 AM - StreetInsider
Press Release: Statement from Sanofi regarding: rule 2.12 of the takeover rules
December 2, 2022 1:55 AM - Globe NewsWire
Midday movers: DoorDash, Workday, Hormel and more
November 30, 2022 12:45 PM - StreetInsider
Horizon Therapeutics seen worth up to $140/share in takeover
November 30, 2022 8:12 AM - StreetInsider
Sanofi (SNY) option IV flat
November 30, 2022 5:58 AM - StreetInsider
After-Hours Movers: Horizon Therapeutics Gains on Takeover Talks, CrowdStrike Sinks on EPS
November 29, 2022 5:56 PM - StreetInsider
3 Rumors Pushing Around Stocks Today
November 29, 2022 5:41 PM - StreetInsider
Horizon Therapeutics (HZNP) jumps after confirming takeover talks with 3 parties
November 29, 2022 5:23 PM - StreetInsider
Horizon Therapeutics (HZNP) Confirms Talks on Takeover With Three Large Pharma Cos.
November 29, 2022 4:26 PM - StreetInsider
Form 6-K Sanofi For: Nov 21
November 21, 2022 10:05 AM - SEC Filing
Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
November 17, 2022 12:50 PM - Globe NewsWire
Form 6-K Sanofi For: Nov 15
November 15, 2022 3:02 PM - SEC Filing
Press Release: Dupixent® (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
November 11, 2022 7:00 AM - Globe NewsWire
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
November 11, 2022 6:59 AM - PR NewsWire
Form 6-K Sanofi For: Nov 10
November 10, 2022 2:01 PM - SEC Filing
Sanofi (SNY) and GSK’s (GSK) next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
November 10, 2022 10:39 AM - StreetInsider
Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
November 10, 2022 10:36 AM - Globe NewsWire
Sanofi (SNY) and AstraZeneca (AZN) Announce EU Approval of Beyfortus
November 4, 2022 5:37 AM - StreetInsider
Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
November 4, 2022 3:00 AM - Globe NewsWire
Full Article List